key: cord-1032469-iybxn8t7
authors: Park, Jin Kyun; Lee, Eun Bong; Shin, Kichul; Sung, Yoon-Kyoung; Kim, Tae Hwan; Kwon, Seong-Ryul; Lee, Myeung Su; Hong, Seung-Jae; Choi, Byoong Yong; Lee, Shin-Seok; Back, Han Joo
title: COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
date: 2021-03-25
journal: J Korean Med Sci
DOI: 10.3346/jkms.2021.36.e95
sha: e38f9b4d59640085b7c6e4af3272858309fe2d54
doc_id: 1032469
cord_uid: iybxn8t7

The coronavirus disease 2019 (COVID-19) pandemic has caused more than 100 million infections and 2 million deaths worldwide. In up to 20% of cases, COVID-19 infection can take a severe, life-threatening course. Therefore, preventive measures such as mask-wearing, hand hygiene, and social distancing are important. COVID-19 vaccines that use novel vaccine technology can prevent up to 95% of infections. However, the uncertainty regarding the efficacy and safety of vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), who are immunocompromised due to underlying immune dysfunction and concomitant immunosuppressive treatment, warrants clear guidance. A task force of the Korean College of Rheumatology formulated a set of vaccination guidance based on the currently available data and expert consensus. The currently available COVID-19 vaccines are considered to be safe and effective. Every patient with AIIRD should receive one of the available COVID-19 vaccines unless contraindicated for medical reasons such as prior allergy/anaphylaxis to the COVID-19 vaccine or its components. Patients should continue immunosuppressive treatment for their underlying AIIRD, including biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs). Corticosteroids should be reduced to the lowest dose possible without aggravating the AIIRD. To improve the vaccine response, methotrexate can be withheld for 1–2 weeks after each vaccination, and the timing of rituximab and abatacept infusion should be adjusted if clinically acceptable. Rheumatologists should play a leading role in educating and vaccinating patients with AIIRD.

As of March 6, 2021, the coronavirus disease 2019 (COVID- 19) pandemic has resulted in 116,061,296 infections and 2,580,050 deaths (https://coronavirus.jhu.edu/map.html). While most cases were mild to moderate, resembling a common cold or flu-like illness, as many as 20% of cases were life-threatening or fatal. 1 The risk factors of severe complications or death include an older age and comorbidities such as diabetes or preexisting respiratory or cardiovascular disease. 2 A proper antiviral immune response in the early phase of COVID-19 infection determines its clinical course and outcome. 3

Autoimmune inflammatory rheumatic disease (AIIRD) is a heterogeneous group of autoimmune diseases primarily affecting the musculoskeletal organs and connective tissue. Each disease is characterized by a distinct type of immune dysfunction, with a unique inflammatory response and cytokine profile. 4 In rheumatoid arthritis (RA), tumor necrosis factor (TNF)-α and interleukin (IL)-6 play a central role, whereas type 1 interferon (IFN) drives the systemic lupus erythematosus (SLE) pathogenesis. 5 As IFN plays a crucial role in antiviral defense, including against COVID-19 infection, SLE patients might respond differently to COVID-19 infection than RA patients. 6 In addition, underlying immune dysfunction and treatment-induced immunosuppression might increase the risk of COVID-19 complications in AIIRD patients. 7,8

How AIIRD affects the infection rate and severity of COVID-19 has not been fully elucidated. The prevalence of COVID-19 among AIIRD patients was reported to be increased compared with the general population. 9, 10 The overall risk of hospitalization and death was not increased or was only slightly increased in AIIRD patients. 10- 13 However, an increased risk of COVID-19 complications was associated with concomitant use of corticosteroids (prednisolone equivalent of > 10 mg/day) and higher disease activity among AIIRD patients. 14, 15 Strikingly, biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) were associated with a reduced risk of severe COVID-19 infection, while conventional DMARDs did not influence infection severity. 10 Therefore, it is important to continue optimal management of AIIRD and to take preventive measures, such as vaccination, to reduce the risk and the severity of COVID-19 infection. 16 Several phase 3 clinical trials of COVID-19 vaccines demonstrated an efficacy of > 95% in preventing COVID-19 infection without an unusual safety signal ( Table 1) . [17] [18] [19] [20] [21] [22] [23] Since AIIRD patients were not routinely included in the vaccination trials, it remains unclear how AIIRD and immunosuppressive therapy will affect the immune response to the COVID-19 vaccine in AIIRD patients. As such, uncertainty about the efficacy and safety of the COVID-19 vaccines, especially the novel mRNA vaccines and viral vector vaccines, in AIIRD patients could lead to hesitancy in both physicians and patients to provide broad COVID-19 vaccination coverage. 24, 25 This article aims to summarize the current knowledge of COVID-19 vaccines and the potential effects of AIIRDs and immunosuppressive treatment on the vaccine response, followed by clinical guidance on COVID-19 vaccination in patients with AIIRDs.

The major antigenic target of COVID-19 vaccines is the surface spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which binds to the angiotensinconverting enzyme 2 receptor on host cells and initiates viral entry into host cells. 26

There are several categories of COVID-19 vaccines: mRNA vaccines, adenovirus vector vaccines, and protein subunit or inactivated virus vaccines. 27 The mRNA vaccines contain mRNA encoding the spike protein of SARS-CoV-2 encapsulated in lipid nanoparticles. Vector vaccines use a replication-defective adenovirus that contains DNA encoding the SARS-CoV-2 viral spike protein. The viral DNA in the replication-defective adenovirus enters host nuclei without modifying the host genome. Both mRNA vaccines and modified adenovirus vectors instruct the host cells to produce the viral spike protein. Since mRNA vaccines and vector vaccines do not contain or induce infectious viral particles, they are considered non-live vaccines. Protein subunit vaccines contain purified viral spike proteins that were produced in vitro, while the inactivated virus vaccine contains killed SARS-CoV-2. 27 All vaccines directly or indirectly deliver the spike protein of SARS-CoV-2 to the host immune system to induce a humoral and cellular immune response.

The mRNA vaccines, BNT162b2 (Pfizer, New York, NY, USA) and mRNA 1273 (Moderna, Cambridge, MA, USA), contain the mRNA in a lipid nanoparticle that contains polyethylene glycol (PEG) in the lipid film as a carrier. Both vaccines showed an efficacy of close to 95% and provided protection beginning approximately 10 days after the first dose. Nanoparticles are temperature-sensitive. 17 increased the vaccine efficacy from 62.1% to 90.0%. In a newer report, delaying the second dose to 12 weeks after the first injection increased the vaccine efficacy from 55.1% to 81.3%. 19 This unusual relationship between vaccine efficacy and dosing interval merits further investigation. Sputnik V also showed an efficacy of 91.6%, without any major safety issues. 20 NVX-CoV2373 (Novavax, Gaithersburg, MD, USA) and CoronaVac (Sinovac, Beijing, China) contain recombinant SARS-CoV-2 glycoprotein and inactivated COVID-19 virus, respectively. 30, 31 Efficacy and safety data on CoronaVac in well-designed clinical trials are pending.

Although vaccines trigger both cellular and humoral immunity, the post-vaccination antibody titer is often used as a surrogate marker for the successful generation of immunity. 32 For example, a serum antibody ratio against influenza strain antigens of ≥ 1/40 is considered a protective response after seasonal influenza vaccination. 33 Currently, the protective antibody titer for COVID-19 vaccination has not been defined. Recent data suggest that cellular immunity might be more important than humoral immunity in clearing SARS-COV-2 virus. 3 A significant proportion (1-10%) of PCR-positive COVID-19 patients were seronegative (i.e., they tested negative for anti-COVID-19 antibodies using commercial test kits), suggesting that an early and robust T cell response against COVID-19 might clear the virus before a B cell response is mounted. 34 Humoral and cellular immune memory declines with distinct kinetics after COVID-19 vaccination, and the circulating antibody titers do not necessarily represent T cell immune memory. 35 Therefore, measuring both antiviral cellular and humoral immunity might be crucial to accurately assess protective immunity after COVID-19 vaccination.

Immunomodulatory medications can impact: 1) AIIRD disease activity, 2) infection risk, and 3) the vaccine response of AIIRD patients. DMARDs suppress the host immune response and AIIRD disease activity, but not necessarily the vaccine response. For example, tocilizumab elicits a strong anti-inflammatory response without suppressing protective humoral responses after vaccination in patients with RA. 36,37 By contrast, abatacept (ABA) and rituximab (RTX) decrease the humoral response to vaccines. A prednisolone equivalent of >10 mg/day was associated with a greater risk of COVID-19 infection, 15 whereas b/tsDMARDs did not increase the COVID-19 infection risk. 10, 38 However, the effects of individual DMARDs on both the host vaccine response and the AIIRD disease activity need to be evaluated in future studies. As of now, the net benefit of DMARD continuation during the COVID-19 pandemic outweighs the associated risks.

The response to influenza vaccination was not suppressed by up to 20 mg/day of prednisone. 39 A higher dose (prednisolone equivalent of > 20 mg/day) was associated with a blunted vaccine response. 40 According to the Centers for Disease Control and Prevention (CDC) recommendations, a prednisolone equivalent of ≥ 20 mg/day for ≥ 2 weeks contraindicates the use of live-attenuated vaccines because of the risk of viral reactivation. 41,42 As COVID-19 vaccines are non-live vaccines with no potential for viral reactivation in vivo, corticosteroids can be continued safely to control the underlying AIIRD. However, corticosteroid use should be kept as low as possible to decrease the risk of COVID-19 complications, since corticosteroids at a prednisone-equivalent dose of > 10 mg/ day can increase the severity of COVID-19 infection. 10,14,38

Methotrexate (MTX) decreases humoral responses to seasonal influenza vaccines and pneumococcal vaccines. In previous studies, temporary discontinuation of MTX for 2 weeks after vaccination increased the humoral vaccine response to seasonal influenza by > 20% without increasing the risk of flares. [43] [44] [45] Data on the effects of hydroxychloroquine, sulfasalazine, and leflunomide on vaccine responses are scarce. Of note, hydroxychloroquine was found not to be beneficial in either the treatment or prevention of COVID-19 infection in SLE patients, and it should not be prescribed to prevent or treat COVID-19 infection. 46

There was no increased risk of developing severe COVID-19 among patients on biological or synthetic DMARDs including Janus kinase (JAK) inhibitors compared with the general population. 38, 47 Blockade of TNF-α or IL-6 did not influence humoral immunity to influenza or pneumococcal vaccines. 36, 48 However, their effects on cellular immunity have been less studied. Since overproduction of TNF-α and IL-6 can drive a detrimental hyper-inflammatory response (cytokine storm) in severe COVID-19 cases, those medications should be continued. 49 Activation of CD28 is critical for initial priming of naïve T cells by antigen presenting cells. 50 Since ABA can significantly decrease the vaccine response, 51,52 it should be administered at least 1 week after the initial dose (but not after the second dose) of COVID-19 vaccine.

RTX depletes B cells, and therefore it can substantially decrease humoral vaccine responses after vaccination. 48,53 However, B cell depletion does not necessarily increase the risk of serious COVID-19 complications, since innate and cellular immunity remain intact to eliminate SARS-CoV-2. 54 It is recommended that RTX be administered at least 1 month after vaccination.

The JAK inhibitor tofacitinib reduced the response to the PPSV-23 pneumococcal vaccine but not to the influenza vaccine. 55 Baricitinib prevented the progression to severe COVID-19 pneumonia and increased the production of antibodies against the SARS-CoV-2 spike protein. 56 Of note, AIIRD patients on IL-1, IL-6, or JAK inhibitors showed a low incidence of COVID-19, suggesting that b/tsDMARDs may inhibit the development of symptomatic/ aggressive COVID-19 infection. 9, 14 Taken together, most DMARDs do not seem to be associated with more severe COVID-19 infection. 57 Therefore, they should be continued in patients during the SARS-CoV-2 pandemic and during vaccination. However, in order to improve the vaccine response, the ABA, RTX, and MTX dosing schedule can be adjusted as clinically feasible. 

The overall benefits of vaccination outweigh any potential risks from the vaccine. Although complete vaccine protection is desired, even partial protection will prevent or reduce the severity of infection. Achieving herd immunity (i.e., ≥ 70% immunity in a population) is critical for containing COVID-19 spread and protecting patients at a high risk of COVID-19 complications who are not eligible for vaccination, such as patients who are allergic to components of the COVID-19 vaccine. 58 Therefore, all patients and healthcare providers should receive the vaccination, according to the national guideline.

To facilitate a broad and timely COVID-19 vaccination response, a Vaccine Task Force, commissioned by the KCR, formulated clinical guidance for COVID-19 vaccination in patients with AIIRD based on the available data from previous vaccination trials in AIIRD patients, complemented by expert opinions. The recommendations were voted on using the Google Forms survey platform. The level of agreement was rated by 22 members of the Vaccination Task Force and the Committee of Health Policy of the KCR as follows: 1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, and 5 = strongly agree. All recommendations had a high level of agreement (Table 3) . This guidance will be subject to frequent modifications as new evidence/data becomes available. 

The mRNA, virus vector, protein subunit, and inactivated virus vaccines will not cause any SARS-CoV-2 infection since viral replication is not possible. Therefore, none of the currently available COVID-19 vaccines will cause COVID-19 infection in AIIRD patients on immunosuppressive treatment.

Common side effects of COVID-19 vaccine include injection site pain, redness and swelling, and a low-grade fever within 1-3 days after injection, and they generally resolve within 1-3 days of onset. These side effects might be stronger after the boost (second) injection and occur more often in younger persons compared with older persons (> 55 years of age). 18,32

Common vaccines do not aggravate the disease activity of AIIRD patients, although the effect of the COVID-19 vaccine on the AIIRD remains unclear.

An immediate, severe allergic reaction to a previous COVID-19 vaccine or its components are contraindications to COVID-19 vaccination.

Anaphylaxis can develop after mRNA vaccination in rare cases (incidence of 1:100,000 with BNT162b2) where an anti-PEG immune response is mounted. In theory, the underlying immune dysfunction and treatment-associated immunosuppression can blunt the vaccine response in AIIRD patients taking immunomodulatory medications. Preferably, the vaccination should be administered before beginning immunosuppressive therapy. DMARDs should be continued during vaccination since withholding DMARDs can increase disease activity, which is associated with worse COVID-19 infection severity and outcomes. Of note, use of b/tsDMARDs may be associated with less severe COVID-19 infection and a decreased mortality rate. 14 MTX, ABA, and RTX can negatively influence the vaccine response. To increase the vaccine response, the timing of those medications can be adjusted if clinically feasible. Temporary discontinuation of methotrexate for 1-2 weeks after each vaccine dose can be considered. The next cycle of RTX should be started 4 weeks after the second vaccine dose. Abatacept should be given 1 week after the first vaccine dose and should be continued after the second vaccine dose. There are not sufficient data on the effect of cyclophosphamide or JAK inhibitors on the vaccine response to make a concrete recommendation. However, intravenous cyclophosphamide should be given 1 week after each vaccine dose. JAK inhibitors may be withheld for 1 week after each vaccine dose.

To date, there is no evidence that vaccines can prevent COVID-19 transmission completely. Therefore, patients should continue all public health measures, including wearing a mask, hand hygiene, and social distancing, to decrease both asymptomatic and symptomatic COVID-19 transmission.

Several effective COVID-19 vaccines with novel mechanisms of action are currently available. COVID-19 vaccines considered to be safe, with a safety profile consistent with other common 8/12 https://jkms.org https://doi.org/10.3346/jkms.2021.36.e95

non-live vaccines. All patients with AIIRD should receive the vaccine unless contraindicated due to a previous allergy to vaccines or their components. In general, immunomodulatory therapy should be safely continued during vaccination. If clinically feasible, MTX, RTX, and ABA should be withheld temporarily during vaccination.

The current vaccination guidance by the vaccination task force of the KCR is subject to frequent updates and modifications as new data on vaccination safety and efficacy in patients with AIIRD become available. As of now, physicians who care for AIIRD patients should play an active role in educating and vaccinating AIIRD patients to protect both the AIIRD patients and the public. Finally, this guidance has been developed to help physicians manage COVID-19 vaccination for AIIRD patients according to their best clinical judgment.

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: a multicentre retrospective study

Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19

Global Rheumatology Alliance physician-reported registry

Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases

Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flare

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Vaccines and related biological products advisory committee meeting

Novavax creating tomorrow's vaccine today: announcement of UK and South Africa trial results

Sinovac announces phase III results of its COVID-19 vaccine

Escaping catch-22 -overcoming Covid vaccine hesitancy

Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial

Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates

Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase

Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis

Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)

Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors

Influence of corticosteroid therapy on the serum antibody response to influenza vaccine in elderly patients with chronic pulmonary diseases

Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

American College of Rheumatology Guideline for the treatment of rheumatoid arthritis

Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Optimal time between the last methotrexate administration and seasonal influenza vaccination in rheumatoid arthritis: post hoc analysis of a randomised clinical trial

Drug treatments for covid-19: living systematic review and network meta-analysis

Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis

To immunosuppress: whom, when and how? That is the question with COVID-19

Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis

Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Baricitinib restrains the immune dysregulation in patients with severe COVID-19

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?

Herd immunity: understanding COVID-19

The practice guideline for vaccinating Korean patients with autoimmune inflammatory rheumatic disease

Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic

Maintaining safety with SARS-CoV-2 vaccines

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

The authors thank the patient representatives for their participation in the town hall meeting.